Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valacyclovir to Suppress HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Persons
NCT00161434Phase 4Completed
- Sponsor
- University of Washington
- Start
- Mar 2003
- Primary completion
- Jun 2006
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of valaciclovir in human immunodeficiency virus infection (HIV) and Herpes Simplex Virus Type 2 Infection (HSV-2) (2 arms), sponsored by University of Washington. Primary endpoint: Reduction in mucosal HIV shedding associated with daily valacyclovir for suppression of HSV-2 reactivation at 18 weeks. Started Mar 2003; status: completed.
02
Drugs
valaciclovir
03
Conditions
human immunodeficiency virus infection (HIV)Herpes Simplex Virus Type 2 Infection (HSV-2)
Beyond the preview
Go deeper on NCT00161434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161434.